


JC07 Rec'd PCT/PTO 29 APR 2005

PCT-

PTO/CS/2005/02



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

119

Application Number

10/520,502

10/520502

Filing Date

January 3, 2005

First Named Inventor

Stern, Peter L.

Art Unit

1645

Examiner Name

Not yet assigned

Attorney Docket Number

021911-001110US

ENCLOSURES (Check all that apply)

☐

Fee Transmittal Form

☐

Fee Attached

☐

Amendment/Reply

☐

After Final

☐

Affidavits/declaration(s)

☐

Extension of Time Request

☐

Express Abandonment Request

☒

Information Disclosure Statement

☐

Drawing(s)

☐

Licensing-related Papers

☐

Petition

☐

Petition to Convert to a Provisional Application

☐

Power of Attorney, Revocation Change of Correspondence Address

☐

Terminal Disclaimer

☐

Request for Refund

☐

CD, Number of CD(s) _____

☐

Landscape Table on CD

☐

After Allowance Communication to TC

☐

Appeal Communication to Board of Appeals and Interferences

☐

Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)

☐

Proprietary Information

☐

Status Letter

☒

Other Enclosure(s) (please identify below):

Form PTO/SB/08B, 15 references, return postcard

☐

Certified Copy of Priority Document(s)

☐

Reply to Missing Parts/ Incomplete Application

☐

Reply to Missing Parts under 37 CFR 1.52 or 1.53

Remarks

The Commissioner is authorized to charge any additional fees to Deposit Account 20-1430.

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name

Townsend and Townsend and Crew LLP

Signature

Printed name

Kawai Lau

Date

April 27, 2005

Reg. No.

44,461

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.


Signature

Typed or printed name

Timothy S. Parker

Date

April 27, 2005



I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

PATENT
Attorney Docket No.: 021911-001110US
Client Reference No.: OBM77CIP

On April 27, 2005

TOWNSEND and TOWNSEND and CREW LLP

By: Timothy S. Parker

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Peter L. Stern, et al.

Application No.: 10/520,502

Filed: January 3, 2005

For: 5T4 ANTIGEN EXPRESSION

Examiner: Not yet assigned

Art Unit: 1645

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT UNDER 37
CFR §1.97 and §1.98

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The additional references cited on attached form PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed. It is respectfully requested that the additional cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.

As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no

representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

Applicant believes that no fee is required for submission of this statement, because this submission is prior to the issuance of a first Office Action on the merits.


However, if a fee is required, the Commissioner is authorized to deduct such fee from the undersigned's Deposit Account No. 20-1430. Please deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,



Kawai Lau
Reg. No. 44,461

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, Eighth Floor
San Francisco, California 94111-3834
Tel: 858-350-6100
Fax: 415-576-0300
KL:tsp
60477181v1



Substitute for Form 1449B/PTO		Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	10/520,502		
		Filing Date	January 3, 2005		
		First Named Inventor	Stern, Peter L.		
		Art Unit	Not yet assigned		
		Examiner Name	Not yet assigned		
Sheet	1	of	1	Attorney Docket Number	021911-001110US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	BC	Ali, A., et al. "The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa", <i>Oral Oncology</i> (2001) 37:57-64	
	BD	Awan, Abida, et al. "5T4 Interacts with TIP-2/GIPC, a PDZ Protein, with Implications for Metastasis", <i>Biochemical and Biophysical Research Communications</i> (2002) 290:1030-1036	
	BE	Carsberg, Catherine J., et al. "Metastasis-Associated 5T4 Antigen Disrupts Cell-Cell Contacts and Induces Cellular Motility in Epithelial Cells", <i>Int. J. Cancer</i> (1996) 68:84-92	
	BF	Carsberg, Catherine J., et al. "Metastasis-associated 5T4 oncofoetal antigen is concentrated at microvillus projections of the plasma membrane", <i>Journal of Cell Science</i> (1995) 108:2905-2916	
	BG	Forsberg, G., et al. "Therapy of human non-small-cell lung carcinoma using antibody targeting of a modified superantigen", <i>British Journal of Cancer</i> (2001) 85(1):129-136	
	BH	Hole, N., et al. "A 72Kd trophoblast glycoprotein defined by a monoclonal antibody", <i>Br. J. Cancer</i> (1988) 57:239-246	
	BI	Hole, N., et al. "Isolation and Characterization of 5T4, A Tumour-Associated Antigen", <i>Int. J. Cancer</i> (1990) 45:179-184	
	BJ	King, Karen W., et al. "Organisation of the mouse and human 5T4 oncofoetal leucine-rich glycoprotein genes and expression in foetal and adult murine tissues", <i>Biochimica et Biophysica Acta</i> (1999) 1445:257-270	
	BK	Mulder, W. Mieke C., et al. "Low Intercellular Adhesion Molecule 1 and High 5T4 Expression on Tumor Cells Correlate with Reduced Disease-free Survival in Colorectal Carcinoma Patients", <i>Clinical Cancer Research</i> (1997) 3:1923-1930	
	BL	Shaw, David M., et al. "Glycosylation and epitope mapping of the 5T4 glycoprotein oncofoetal antigen" <i>Biochem J.</i> (2002) 363:137-145	
	BM	Southall, P.J., et al. "Immunohistological distribution of 5T4 antigen in normal and malignant tissues", <i>Br. J. Cancer</i> (1990) 61:89-95	
	BN	Starzynska T., et al. "Prognostic significance of 5T4 oncofoetal antigen expression in colorectal carcinoma", <i>Br. J. Cancer</i> (1994) 69:899-902	
	BO	Starzynska, T., et al. "The expression of 5T4 antigen in colorectal and gastric carcinoma", <i>Br. J. Cancer</i> (1992) 66:867-869	
	BP	Starzynska, T., et al. "5T4 oncofoetal antigen in gastric carcinoma and its clinical significance", <i>European Journal of Gastroenterology & Hepatology</i> (1998) 10(6):479-484	
	BQ	Wrigley, E., et al. "5T4 oncofoetal antigen expression in ovarian carcinoma", <i>Int. J. Gynecol Cancer</i> (1995) 5:269-274	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.